Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01843374 · OUTCOME

OS Rate at 18 Months by Treatment Arm

Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma · Source last updated 2026-07-27

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
Percentage of Participants
Interval / dispersion
95% Confidence Interval
Time frame
18 months

What was measured

The percentage of patients still alive at 18 months

Analysis population: ITT population

Groups in this outcome

TREMELIMUMAB

Tremelimumab 10mg/kg

PLACEBO

Placebo.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
TREMELIMUMAB382
PLACEBO189

Reported measurements

Source class 1
Values in Percentage of Participants · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
TREMELIMUMAB17.4Not reported13.421.8Not reported
PLACEBO18.2Not reported12.724.5Not reported

Source statistical analyses

Group order, estimate direction, methods and comments are retained. No treatment ranking is inferred.

  1. ci Lower Limit
    0.793
    ci Num Sides
    TWO_SIDED
    ci Pct Value
    95
    ci Upper Limit
    1.289
    estimate Comment
    Tremelimumab is the numerator and Placebo the denominator
    group Ids
    1. OG000
    2. OG001
    non Inferiority Type
    SUPERIORITY_OR_OTHER_LEGACY
    p Value
    0.926
    p Value Comment
    Estimated using the methods of Klein et al. 2007 and Whitehead and Whitehead 1991, stratified by EORTC status and line of therapy.
    param Type
    Hazard Ratio (HR)
    param Value
    1.011
    statistical Method
    Log Rank
Complete source fields
analyses
  1. ci Lower Limit
    0.793
    ci Num Sides
    TWO_SIDED
    ci Pct Value
    95
    ci Upper Limit
    1.289
    estimate Comment
    Tremelimumab is the numerator and Placebo the denominator
    group Ids
    1. OG000
    2. OG001
    non Inferiority Type
    SUPERIORITY_OR_OTHER_LEGACY
    p Value
    0.926
    p Value Comment
    Estimated using the methods of Klein et al. 2007 and Whitehead and Whitehead 1991, stratified by EORTC status and line of therapy.
    param Type
    Hazard Ratio (HR)
    param Value
    1.011
    statistical Method
    Log Rank
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        13.4
        upper Limit
        21.8
        value
        17.4
      2. group Id
        OG001
        lower Limit
        12.7
        upper Limit
        24.5
        value
        18.2
denom Units Selected
Participants
denoms
  1. counts
    1. group Id
      OG000
      value
      382
    2. group Id
      OG001
      value
      189
    units
    Participants
description
The percentage of patients still alive at 18 months
dispersion Type
95% Confidence Interval
groups
  1. description
    Tremelimumab 10mg/kg
    id
    OG000
    title
    TREMELIMUMAB
  2. description
    Placebo.
    id
    OG001
    title
    PLACEBO
param Type
NUMBER
population Description
ITT population
reporting Status
POSTED
time Frame
18 months
title
OS Rate at 18 Months by Treatment Arm
type
SECONDARY
type Units Analyzed
Participants
unit Of Measure
Percentage of Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice